NDPS Act, Bhang Exception, Charas & Goa Situation – Your Complete 2026 Legal Guide
| Recreational Use (Ganja/Charas) | Illegal – NDPS Act 1985 |
| Bhang (Leaves/Seeds) | Legal in Most States – Licensed Shops |
| Charas (Hash) | Illegal – Serious Penalties |
| Medical Cannabis | Very Limited – No Public Program |
| Tourist Risk | High – 10-20 Years for Commercial Qty |
| Category | Status | Details |
|---|---|---|
| Ganja (Flower) | Illegal | Prohibited under NDPS Act; small quantity up to 1 year; commercial quantity 10–20 years |
| Charas (Hash) | Illegal | Explicitly prohibited; same penalties as ganja; Parvati Valley charas actively seized |
| Bhang (Leaves/Seeds) | Legal in Many States | Exempt from NDPS Act; state-licensed bhang shops in UP, Rajasthan, and others |
| Medical Cannabis | Very Limited | Epidyolex approved for rare epilepsy; no comprehensive patient program |
| Home Cultivation | Illegal | Unlicensed cultivation prohibited under NDPS; hemp cultivation requires state government license |
| Driving Under Influence | Criminal Offence | Motor Vehicles Act Section 185; blood tests at checkpoints in major cities |
| Tourist Access | Illegal – Very High Risk | Foreigners subject to same NDPS penalties; arrested tourists face lengthy pre-trial detention |
India's primary cannabis legislation is the Narcotic Drugs and Psychotropic Substances (NDPS) Act of 1985, enacted under pressure from international drug control conventions including the 1961 UN Single Convention on Narcotic Drugs. The NDPS Act classifies cannabis (ganja — the flowering or fruiting tops of the cannabis plant) and charas (cannabis resin) as prohibited narcotic substances. Penalties are structured around quantity thresholds: possession of quantities below the "small quantity" threshold (typically interpreted as under 100 grams of ganja or 5 grams of charas for personal use under Section 27) carries up to 1 year imprisonment and/or a fine. Possession between the small and commercial quantity thresholds carries a rigorous 1 to 10 year sentence. Commercial quantity possession — defined in the schedule as 1 kg of charas or 20 kg of ganja — carries a mandatory minimum of 10 years imprisonment with a maximum of 20 years, plus a fine of up to 2 lakh rupees.
The bhang exemption is the NDPS Act's most discussed provision. Section 2(iii)(b) defines cannabis to include ganja and charas but explicitly excludes "any preparation of cannabis seeds or leaves not involving the use of resin." This exemption reflects the deep cultural, religious, and economic role of bhang — cannabis leaf preparations consumed as drinks, sweets, and food — in Hindu traditions. Bhang has been consumed in religious ceremonies to Shiva for thousands of years and remains central to Holi and Maha Shivratri festivals. The exemption has allowed state governments to license and regulate bhang sales independently. States including Uttar Pradesh (with famous bhang shops in Varanasi), Rajasthan (Pushkar, Jaisalmer, Jaipur), Uttarakhand, and Bihar maintain licensing systems for bhang shops and lassi vendors. The potency of licensed bhang preparations varies considerably, and bhang lassi sold at licensed shops can be significantly stronger than tourists anticipate.
The Parvati Valley in Himachal Pradesh (Kheerganga, Kasol, Malana) and certain areas of Uttarakhand and Goa have developed reputations as cannabis-tolerant zones, driven by their history as hippie trail destinations from the 1960s and 1970s and by the genuine cultural presence of cannabis in local agricultural traditions. Malana, a Himalayan village, produces Malana Cream — a hand-rubbed charas famous globally for its potency and unique characteristics. Despite this fame, Malana Cream remains fully illegal under the NDPS Act, and police operations targeting production and possession in the Parvati Valley occur regularly. The Himachal Pradesh Police conduct annual anti-drug campaigns, and foreign nationals found with charas in the Parvati Valley face the same NDPS penalties as anyone else.
India's legal reform debate has intensified since 2019, driven partly by the economic opportunity in licensed cannabis and hemp industries and partly by public health research showing that cannabis penalties fall disproportionately on marginalized communities. The Parliamentary Standing Committee on Finance's 2019 report recommended consideration of cannabis decriminalization. Several state governments — including Himachal Pradesh, Uttarakhand, and Manipur — have licensed industrial hemp cultivation for fiber and seed. A Ministry of Social Justice and Empowerment report in 2023 recommended decriminalizing small quantity possession. However, as of 2026, no national legislative reform has occurred, and the NDPS Act penalties remain in full force.
| Offense | Quantity | Penalty | Enforcement Reality |
|---|---|---|---|
| Small Quantity Possession | Ganja <100g / Charas <5g | Up to 1 year + fine (Sec. 27) | Police discretion wide; bail generally obtainable; foreigners often face bribe demands first |
| Intermediate Quantity | Between small and commercial | 1–10 years + fine | Bail harder to obtain; pre-trial detention common; judicial process slow |
| Commercial Quantity | Charas >1kg / Ganja >20kg | 10–20 years mandatory minimum | No bail at commercial quantities; years of pre-trial custody before judgment common |
| Trafficking / Production | Supply intent | 10–20 years | Separate from possession; production for supply, financing, organization all carry same range |
| Bhang (State Licensed) | Leaf preparation only | Legal where licensed by state | Licensed shops operate in UP, Rajasthan, and others; check state-specific rules |
India's medical cannabis framework is extremely limited relative to the country's size and potential. The only cannabis-derived medication approved by the Central Drugs Standard Control Organisation (CDSCO) as of 2026 is Epidyolex (cannabidiol) for treatment-resistant Dravet syndrome and Lennox-Gastaut syndrome in children. Approval came in 2023, following international precedents. Access remains highly restricted to specialized pediatric neurology centers and requires exceptional circumstances documentation. The medication costs approximately 30,000 to 50,000 INR per month — prohibitively expensive for most Indian families — and is not covered by government health schemes.
Several state governments have moved to license industrial hemp cultivation, creating a quasi-legal framework that is adjacent to medical cannabis. Uttarakhand became the first state to license hemp cultivation in 2017, permitting licensed farmers to grow low-THC hemp for fiber and seeds. Himachal Pradesh, Manipur, Madhya Pradesh, and Rajasthan have followed with similar programs. These hemp programs have generated pharmaceutical interest in CBD extraction — several companies have received state licenses to extract and process CBD for pharmaceutical purposes, though the regulatory pathway for CBD products in India remains unclear, with CDSCO issuing inconsistent guidance.
The Indian Council of Medical Research (ICMR) and several premier medical institutions including AIIMS (All India Institute of Medical Sciences) have conducted cannabinoid research, particularly in pain management and oncology. Researchers have advocated for expanded access to cannabinoid medicines. However, the political environment for reform remains constrained by coalition politics, moral concerns among religious stakeholders, and security concerns about loosening drug laws in a country bordering major opium-producing regions. The Ministry of Health's 2023 task force on palliative care made specific recommendations for limited medical cannabis access that have not yet been implemented legislatively.
India's cannabis economy is vast but primarily illicit. The country has a long history of cannabis cultivation, with wild-growing cannabis (commonly called "nasha" in northern regions) widespread across the Himalayan foothills, the Deccan Plateau, and parts of northeastern India. Himachal Pradesh's Parvati Valley, Kullu Valley, and Spiti produce charas (hand-rubbed hash) that commands premium prices in European and global markets. UNODC estimates India produces several hundred tonnes of charas annually, representing a significant portion of the global resin supply alongside Moroccan and Afghan production.
The licensed industrial hemp sector has grown to include over 50 licensed cultivation operations across Uttarakhand, Himachal Pradesh, and Manipur, with a combined licensed cultivation area of approximately 8,000 to 12,000 hectares as of 2025. Several startups — including IHF (Indian Hemp Foundation) and brands like The Eco Company and Boheco (Bombay Hemp Company) — have positioned themselves in the hemp fiber, seed oil, and CBD extract market. However, the CBD market operates in regulatory uncertainty, as CDSCO has not issued comprehensive guidelines distinguishing hemp CBD from prohibited cannabis products.
India's licensed bhang economy generates substantial revenue through state excise systems. Uttar Pradesh alone licenses approximately 600 to 700 bhang shops, generating tens of crores in annual excise revenue. The Holi festival season drives concentrated bhang sales nationally. Bhang thandai (a spiced milk drink) and bhang pakoras are central to religious celebrations in northern India, with consumption during Holi considered culturally mainstream even by many non-users. This cultural normalization of bhang exists in complex tension with the criminalization of other cannabis preparations under the NDPS Act.
Cannabis has been used in India for at least 3,000 to 4,000 years, with references appearing in the Atharva Veda (one of the four Hindu sacred texts, circa 1500-1200 BCE), which lists cannabis (bhanga) among five sacred plants. The Shaivite tradition of Hindu practice associates cannabis with Shiva, the destroyer and transformer deity — according to legend, cannabis is Shiva's favorite plant. Sadhus (wandering Hindu ascetics) have used cannabis for meditative and devotional purposes for centuries, smoking it in clay chillums as an aid to spiritual practice. This sacred association gives cannabis a distinct cultural status in India that differs fundamentally from its treatment in Western countries — cannabis is simultaneously a prohibited drug under modern law and a divinely sanctioned substance in ancient religious tradition.
The Parvati Valley of Himachal Pradesh occupies a unique position in modern cannabis culture. The valley's isolation, altitude (1,800 to 4,500 meters), and ecology create conditions for exceptionally resinous cannabis production. The charas produced through hand-rubbing of live plants has been traded locally for generations and became internationally famous after the hippie trail of the 1960s and 1970s brought Western travelers through the valley. Villages like Malana, Kasol, and Kheerganga became pilgrimage sites for cannabis tourists. Malana Cream — the hand-rubbed charas from Malana village — achieved legendary status in European cannabis markets for its distinctive smell, taste, and potency, fetching prices of 5,000 to 15,000 INR per tola (11 grams) locally and multiples more in European retail.
India's relationship with cannabis reflects profound historical tensions. The 1894 Indian Hemp Drugs Commission Report, commissioned by the British colonial government, is one of history's most thorough investigations of cannabis use — the commission concluded that moderate use of bhang was relatively harmless and recommended against complete prohibition. The colonial government ultimately regulated rather than prohibited cannabis. Post-independence India followed international drug control conventions with the NDPS Act of 1985, creating the current contradiction between millennia of cultural integration and modern criminal prohibition. Contemporary advocates for reform often cite the Hemp Commission report and the Vedic tradition as evidence that prohibition is a colonial imposition incompatible with Indian cultural heritage.
India is a very high-risk destination for cannabis tourists despite its cultural associations with the plant. The NDPS Act penalties are among the harshest in Asia. Pre-trial detention is common and can last years. Foreigners are not exempt from any provision. Goa, the Parvati Valley, and Varanasi all carry significant risk despite their reputations. Only bhang at licensed shops is genuinely safe and legal.
Health & Science writer with nursing background, specializing in medical cannabis research.
Cannabis (ganja and charas) is illegal under the NDPS Act 1985. Small quantity possession carries up to 1 year; commercial quantities carry 10 to 20 years. Bhang (leaf/seed preparations) is legally exempt in most states. No recreational legalization has occurred as of 2026.
Bhang is a cannabis leaf and seed preparation deeply embedded in Hindu religious tradition. The NDPS Act exempts cannabis leaves from prohibition, allowing state governments to license bhang shops. Licensed bhang lassi, thandai, and sweets are legally sold in UP, Rajasthan, and other states.
Goa has informal tolerance around beach party culture, but cannabis remains fully illegal under the NDPS Act. Police operations target drug use at beach parties regularly. Foreigners are arrested, and India’s drug laws apply equally regardless of nationality or the local reputation for tolerance.
Charas is hand-rubbed cannabis resin produced in Himachal Pradesh and Kashmir. It is explicitly prohibited under the NDPS Act and not covered by the bhang exemption. Despite being a famous Indian tradition, charas possession carries penalties of 1 to 20 years depending on quantity.
Uttar Pradesh (Varanasi, Mathura), Rajasthan (Jaipur, Pushkar, Jaisalmer), Uttarakhand, and Bihar license bhang shops under state excise law. These shops legally sell bhang leaf preparations. State licensing is distinct from any permission for flowers, hash, or other cannabis products.